Developer docs
API playgroundTry for free, no card

Search company profiles

Proteon Pharmaceuticals

Full company profile

uuid0002fsm

Namestring
Proteon Pharmaceuticals
Legal namestring
Proteon Pharmaceuticals S.A.
Company typeenum
Private
Founded yearint
2005
Descriptiontext

PROTEON uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. We have developed a platform to develop and deliver bacteriophages for animal health solutions. Our pipeline includes solutions to prophylactically improve performance and food safety in poultry, as well as important prevent economically important bacterial diseases in aquaculture and dairy.

Short descriptiontext

Proteon Pharmaceuticals is an innovative biotech company.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLodz, Poland
HQ citystring
Lodz
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bacteriophage therapeutics, animal health biopharmaceuticals, antibiotic alternatives, aquaculture health solutions, livestock microbiome solutions
Industry3 codes
PRIMARYAFADALAO
Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support)
SECONDARYAFADALAE
Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials)
SECONDARYAFAJAKAE
Probiotics (Strains, Spore-Formers, Synbiotic Components)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Animal Health Biologics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Bacteriophage-based Solutions
TypeOthers
Description

The company generates revenue through the sale of bacteriophage-based products and solutions for the aquaculture and livestock markets. These products are designed to reduce antibiotic use in farming, targeting sustainable and health-conscious protein production globally.

thefishsite.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Proteon Pharmaceuticals develops and sells bacteriophage-based products for livestock and aquaculture that serve as alternatives to traditional antibiotics in animal farming. The company applies its microbiome platform technology—integrating AI, high-throughput screening, and process automation—to identify and produce targeted bacteriophage formulations that maintain animal health and support sustainable protein production. Its offerings are aimed at large-scale farming operations seeking to reduce antibiotic use amid regulatory and market pressure for sustainable practices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduction of antibiotic use in agriculture
+2 more records
Product overview1 text field

Proteon Pharmaceuticals offers bacteriophage-based solutions for livestock and aquaculture. Their microbiome platform technology provides sustainable alternatives to antibiotics in agriculture, targeting animal health and sustainable protein production. The company develops solutions aimed at reducing antibiotic use in livestock farming and aquaculture. No individual named products or modules are explicitly identified in the available sources.

Product and service1 record
1Bacteriophage-based solutions for livestock and aquaculture
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Phagelux
TypeDirect peer
Description

Phagelux develops bacteriophage-based products targeting animal health, food safety, and agricultural applications. It is the closest direct competitor to Proteon in animal/agriculture phage products, addressing similar customer pain points around antibiotic reduction.

2Intralytix
TypeDirect peer
Description

Intralytix is a pioneer in bacteriophage products, with animal health and food safety applications. Its overlapping product categories and phage R&D capability make it a direct comparable to Proteon.

3Micreos
TypeDirect peer
Description

Micreos develops phage-based applications targeting bacteria across food safety and animal health. Its commercialization model in animal protein supply chains closely mirrors Proteon's positioning.

4Fixed Phage
TypeDirect peer
Description

Fixed Phage is a UK-based phage technology company applying bacteriophages to animal health and agricultural challenges. Its narrow focus on phage technology for livestock and aquaculture makes it a direct comparable.

5Eligo Bioscience
TypeEmerging player
Description

Eligo Bioscience engineers phage-based products to modulate microbiomes, including in animal health applications. It is an emerging player with overlapping platform technology to Proteon's microbiome approach.

6BiomX
TypeEmerging player
Description

BiomX develops phage-based therapies primarily for human health but applies a similar phage discovery and engineering platform. Its technology approach is thematically comparable to Proteon's AI-driven phage platform.

7Locus Biosciences
TypeEmerging player
Description

Locus Biosciences develops engineered bacteriophage products for antimicrobial applications. Its platform-based approach to phage R&D is comparable to Proteon's high-throughput screening and AI integration strategy.

8Elanco Animal Health
TypeBroad incumbent
Description

Elanco is a large incumbent in animal health and nutrition with broad portfolios in livestock and aquaculture. It competes with Proteon as a buyer-facing supplier and could acquire or displace phage-based alternatives.

9Zoetis
TypeBroad incumbent
Description

Zoetis is the world's largest animal health company, offering vaccines, diagnostics, and feed additives across livestock and aquaculture. It represents the broad incumbent competitive threat to niche phage developers like Proteon.

10Phibro Animal Health
TypeBroad incumbent
Description

Phibro Animal Health supplies nutritional and health products for livestock and aquaculture, including antibiotic alternatives. Its incumbent position in animal protein supply chains makes it a relevant comparator for go-to-market dynamics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Proteon Pharmaceuticals

Animal Health Biologicsproteonpharma.com

Proteon Pharmaceuticals is an innovative biotech company.

What Proteon Pharmaceuticals does

PROTEON uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. We have developed a platform to develop and deliver bacteriophages for animal health solutions. Our pipeline includes solutions to prophylactically improve performance and food safety in poultry, as well as important prevent economically important bacterial diseases in aquaculture and dairy.

Proteon Pharmaceuticals firmographics

Firmographics
Name
Proteon Pharmaceuticals
Legal name
Proteon Pharmaceuticals S.A.
Website
https://proteonpharma.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
1–10 employees
Short description
Proteon Pharmaceuticals is an innovative biotech company.
Ownership category
akta.pro rank

Proteon Pharmaceuticals industry classification

Industry
Product category
Animal Health Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYAFADALAO
Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support)
SECONDARYAFADALAE
Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials)
SECONDARYAFAJAKAE
Probiotics (Strains, Spore-Formers, Synbiotic Components)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)

Keywords

  • Bacteriophage therapeutics
  • Animal health biopharmaceuticals
  • Antibiotic alternatives
  • Aquaculture health solutions
  • Livestock microbiome solutions

Where Proteon Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Lodz
HQ country
Poland
HQ region
Europe

Offices1 record

Markets served

Proteon Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Bacteriophage-based Solutions: The company generates revenue through the sale of bacteriophage-based products and solutions for the aquaculture and livestock markets. These products are designed to reduce antibiotic use in farming, targeting sustainable and health-conscious protein production globally.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Proteon Pharmaceuticals product offering

Product offering

Core offering

Proteon Pharmaceuticals develops and sells bacteriophage-based products for livestock and aquaculture that serve as alternatives to traditional antibiotics in animal farming. The company applies its microbiome platform technology—integrating AI, high-throughput screening, and process automation—to identify and produce targeted bacteriophage formulations that maintain animal health and support sustainable protein production. Its offerings are aimed at large-scale farming operations seeking to reduce antibiotic use amid regulatory and market pressure for sustainable practices.

Product overview

Proteon Pharmaceuticals offers bacteriophage-based solutions for livestock and aquaculture. Their microbiome platform technology provides sustainable alternatives to antibiotics in agriculture, targeting animal health and sustainable protein production. The company develops solutions aimed at reducing antibiotic use in livestock farming and aquaculture. No individual named products or modules are explicitly identified in the available sources.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bacteriophage-based solutions for livestock and aquaculture

Quantifiable outcome

  • Reduction of antibiotic use in agriculture
  • +2 more outcomes

Companies that use Proteon Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Proteon Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Proteon Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Proteon Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Phagelux: Phagelux develops bacteriophage-based products targeting animal health, food safety, and agricultural applications. It is the closest direct competitor to Proteon in animal/agriculture phage products, addressing similar customer pain points around antibiotic reduction.
  • Intralytix: Intralytix is a pioneer in bacteriophage products, with animal health and food safety applications. Its overlapping product categories and phage R&D capability make it a direct comparable to Proteon.
  • Micreos: Micreos develops phage-based applications targeting bacteria across food safety and animal health. Its commercialization model in animal protein supply chains closely mirrors Proteon's positioning.
  • Fixed Phage: Fixed Phage is a UK-based phage technology company applying bacteriophages to animal health and agricultural challenges. Its narrow focus on phage technology for livestock and aquaculture makes it a direct comparable.

Emerging players

  • Eligo Bioscience: Eligo Bioscience engineers phage-based products to modulate microbiomes, including in animal health applications. It is an emerging player with overlapping platform technology to Proteon's microbiome approach.
  • BiomX: BiomX develops phage-based therapies primarily for human health but applies a similar phage discovery and engineering platform. Its technology approach is thematically comparable to Proteon's AI-driven phage platform.
  • Locus Biosciences: Locus Biosciences develops engineered bacteriophage products for antimicrobial applications. Its platform-based approach to phage R&D is comparable to Proteon's high-throughput screening and AI integration strategy.

Broad incumbents

  • Elanco Animal Health: Elanco is a large incumbent in animal health and nutrition with broad portfolios in livestock and aquaculture. It competes with Proteon as a buyer-facing supplier and could acquire or displace phage-based alternatives.
  • Zoetis: Zoetis is the world's largest animal health company, offering vaccines, diagnostics, and feed additives across livestock and aquaculture. It represents the broad incumbent competitive threat to niche phage developers like Proteon.
  • Phibro Animal Health: Phibro Animal Health supplies nutritional and health products for livestock and aquaculture, including antibiotic alternatives. Its incumbent position in animal protein supply chains makes it a relevant comparator for go-to-market dynamics.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights5 records

Customer concentration

Proteon Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Proteon Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles9 records

Proteon Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Proteon Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proteon Pharmaceuticals

What does Proteon Pharmaceuticals do?

Proteon Pharmaceuticals develops and sells bacteriophage-based products for livestock and aquaculture that serve as alternatives to traditional antibiotics in animal farming. The company applies its microbiome platform technology—integrating AI, high-throughput screening, and process automation—to identify and produce targeted bacteriophage formulations that maintain animal health and support sustainable protein production. Its offerings are aimed at large-scale farming operations seeking to reduce antibiotic use amid regulatory and market pressure for sustainable practices.

Is Proteon Pharmaceuticals a public or private company?

Proteon Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Proteon Pharmaceuticals founded?

Proteon Pharmaceuticals was founded in 2005. It employs 1 to 10 people.

Where is Proteon Pharmaceuticals based?

Proteon Pharmaceuticals is headquartered in Lodz, Poland, in the Europe region.

How does Proteon Pharmaceuticals make money?

One revenue line is on record: bacteriophage-based Solutions.

Who are Proteon Pharmaceuticals's main competitors?

Direct peers on record are Phagelux, Intralytix, Micreos and Fixed Phage. Emerging players are Eligo Bioscience, BiomX and Locus Biosciences. Broad incumbents are Elanco Animal Health, Zoetis and Phibro Animal Health.

Does Proteon Pharmaceuticals have an API?

No public API is recorded for Proteon Pharmaceuticals.

What industry is Proteon Pharmaceuticals in?

Proteon Pharmaceuticals's product category is Animal Health Biologics. Its primary akta.pro industry code is AFADALAO, Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support), with a secondary code of AFADALAE, Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Fish SiteBacteriophage startup secures €21 million fundingPolish bacteriophage startup Proteon Pharmaceuticals has secured €21 million in Series funding to support global product roll-out and further develop its microbiome platform technology using AI, high throughput screening, and process automation. The financing round was led by Nutreco, Aqua-Spark, and PFR Life Science, with participation from Montis Capital, Seventure Partners, and angel investors. The company plans to use the funds to reduce antibiotic use in livestock farming and promote sustainable protein production, targeting the aquaculture and livestock markets with its bacteriophage-based solutions.Global Seafood AllianceA review of bacteriophage therapy in aquacultureA review article examines the application of bacteriophage therapy as an alternative to antibiotics for treating bacterial diseases in freshwater and saltwater aquaculture. The text highlights Proteon Pharmaceuticals as a company poised to expand its bacteriophage products for this sector, addressing economic losses caused by pathogens like Vibrio spp. in fish, mollusks, and crustaceans.SkrettingHealth & welfareSkretting outlines its RoadMap 2025 targets to address antimicrobial resistance by eliminating prophylactic antibiotic use and restricting critically important antibiotics to prescription-only veterinary treatments. The company is actively collaborating with partners like Proteon Pharmaceuticals to develop bacteriophage alternatives for fish and shrimp health management while supporting customers in achieving antibiotic-free production standards.Poultry WorldProfessor Jaroslaw Dastych: Novel antibacterial solution for poultryProteon Pharmaceuticals is promoting its bacteriophage-based products, specifically the Bafasal+G feed additive for poultry, as an alternative to antibiotics to combat antimicrobial resistance and improve food safety. The company states that its technology effectively targets pathogens like Salmonella without leaving residues or contributing to bacterial resistance, aligning with rising consumer demand for antibiotic-free food.Business Wire IndiaProteon Pharmaceuticals Secures 21 Million Euro and Takes Another Step Towards Sustainability in Animal HealthcareProteon Pharmaceuticals secured a €21 million financing round led by Nutreco, Aqua-Spark, and PFR Life Science to accelerate the commercialization of its bacteriophage products in livestock and aquaculture. The investment aims to reduce antibiotic usage in farming and expand the company's global reach for its sustainability-focused health solutions. This funding supports ongoing development with partners like Skretting to deepen their relationship in developing alternative antibacterial treatments.ProteonpharmaProteon Pharmaceuticals Secures 21 million Euro to Accelerate GrowthProteon Pharmaceuticals secured a 21 million Euro investment led by Nutreco, Aqua-Spark, and PFR Life Science to accelerate the commercialization of its bacteriophage-based products for livestock and aquaculture. The funding will support global product rollout, expansion of production capacity, and the integration of AI tools into its microbiome platform technology. This strategic move aims to reduce reliance on antibiotics in animal farming and promote sustainable protein production.ProteonpharmaEFSA confirms safety of BAFASAL®, A “First in Class”, innovative feed additiveProteon Pharmaceuticals reported that the European Food Safety Authority concluded in its first evaluation of a bacteriophage feed additive that BAFASAL® is safe for all avian species, poultry consumers and the environment, with no concerns over manufacturing quality. Proteon said EFSA's efficacy assessment remains pending, with EU authorization expected by late 2021 or early 2022.PrwebDuPont Animal Nutrition to Partner with Proteon Pharmaceuticals in the Poultry IndustryDuPont Animal Nutrition announced a partnership with Proteon Pharmaceuticals to bring bacteriophage technology to poultry producers in selected countries. The collaboration aims to strengthen gut health solutions and mitigate antimicrobial resistance, with Proteon's technology already used in animal food.AgFunderNewsAquaculture Fund Aqua-Spark Moves Beyond Farms and Feed With Two New InvestmentsAqua-Spark, a Dutch aquaculture VC fund, invested in Proteon Pharmaceuticals and Cryoocyte. Proteon raised €3.5 million for a salmonella preventative using bacteriophages, while Cryoocyte raised $4 million for a cooling and storage method. The fund has €49.4 million under management and plans 60-80 investments over 15 years.